Barrett’s oesophagus

Barrett’s oesophagus is a change in the tissue lining the lower part of the oesophagus, primarily associated with prolonged exposure to gastro-oesophageal reflux. Its clinical significance lies in correctly identifying its characteristics and establishing a follow-up programme tailored to each individual’s risk.

What is Barrett’s oesophagus?

The oesophagus is the tube that carries food from the mouth to the stomach. Its interior is lined with tissue designed to withstand the friction caused by swallowing. In Barrett’s oesophagus, part of this lining is replaced by tissue with different characteristics, more similar to that found in the intestine. This change is known as intestinal metaplasia.

Over time, some of these cells may undergo abnormal changes, known as dysplasia. Identifying this is important because it allows for a better assessment of the risk of progression and helps determine the most appropriate follow-up or treatment. To confirm the diagnosis, simply observing a change in appearance during an endoscopy is not enough. It is necessary to analyse small tissue samples, known as biopsies, and check under a microscope that intestinal metaplasia is present.

In Spain and other European countries, changes measuring less than one centimetre at the junction between the oesophagus and the stomach are not usually considered to be Barrett’s oesophagus and do not require specific endoscopic monitoring.

Causes and associated factors

Barrett’s oesophagus is primarily associated with repeated exposure of the oesophagus to stomach contents, as occurs in gastro-oesophageal reflux disease. Acid and other gastric components can cause sustained irritation to the mucosa. In some people, the normal lining is replaced by tissue with different characteristics.

This change can be understood as an adaptation to prolonged exposure, although the new tissue retains a greater capacity to develop cellular abnormalities over time. Not everyone with reflux develops Barrett’s oesophagus. Factors such as the duration of the condition, the frequency of reflux, the presence of a hiatal hernia, abdominal obesity and other individual factors all play a role.

Some people diagnosed with the condition have never experienced clear-cut heartburn or regurgitation. The absence of symptoms does not rule out the possibility that the oesophagus has been exposed to reflux for years.

Risk factors

Barrett’s oesophagus is more common in people with chronic reflux who also have other risk factors. The likelihood is particularly high in men over the age of 50, people with abdominal obesity, smokers or former smokers, and patients with a family history of Barrett’s oesophagus or oesophageal adenocarcinoma.

The presence of just one of these factors does not in itself mean that an endoscopy is necessary. Screening is usually considered when several factors are present and should be decided on a case-by-case basis. For this reason, routine screening endoscopies are not recommended for everyone who experiences heartburn or reflux. The decision must take into account the duration of symptoms, age, sex, family history and the overall set of risk factors.

Symptoms

Barrett’s oesophagus does not usually cause any symptoms of its own. When symptoms do occur, they are usually due to associated gastro-oesophageal reflux. The most common symptoms are a burning sensation behind the breastbone, regurgitation and discomfort that worsens after eating or when lying down.

Some people experience difficulty swallowing, chest pain, a cough or hoarseness. These symptoms can have many other causes and do not, on their own, allow a diagnosis of Barrett’s oesophagus. In many cases, the condition is discovered during an endoscopy carried out to investigate persistent reflux, difficulty swallowing, anaemia or some other clinical reason.

Nor does the severity of reflux allow the risk of progression to be assessed. One person may have few symptoms and an extensive segment of Barrett’s oesophagus, whilst another may experience severe heartburn without having this condition.

Symptoms requiring medical assessment

Progressive difficulty swallowing, a sensation that food is getting stuck, pain when swallowing, unintentional weight loss, anaemia or gastrointestinal bleeding require medical assessment. Persistent vomiting or a rapid worsening of symptoms that were previously stable should also be investigated.

These symptoms may be due to inflammation, a narrowing of the oesophagus, a motility disorder or another condition that needs to be investigated. Severe or sudden-onset chest pain should be assessed as a priority, as it may have a cardiovascular cause and should not automatically be attributed to reflux.

Diagnosis

The diagnosis is made by means of a gastroscopy, also known as an upper gastrointestinal endoscopy or oesophagogastroduodenoscopy, involving the taking of biopsies. These are different terms for a procedure that allows direct visualisation of the oesophagus, stomach and duodenum. During the examination, the specialist checks for any area of abnormal mucosa in the lower part of the oesophagus and records its extent. To describe this in a standardised way, the Prague classification may be used, a system that measures the length of the affected tissue.

The appearance observed during the endoscopy is not sufficient to confirm the diagnosis. Small tissue samples must be taken and examined under a microscope to check for intestinal metaplasia and to see whether the cells show any abnormal changes. The quality of the endoscopy and the correct taking of biopsies are essential. Cellular changes may be found in small areas and are not always visible to the naked eye.

For this reason, the entire surface of the Barrett’s oesophagus is examined carefully, targeted samples are taken from any visible lesions, and systematic biopsies are taken from different areas of the tissue.

Treatment

Treatment depends mainly on whether the biopsies show dysplasia, the severity of the changes and the presence of a visible lesion. Everyone with Barrett’s oesophagus should receive appropriate management of their reflux. Proton pump inhibitors, such as omeprazole or pantoprazole, reduce acid production and are usually part of the treatment.

These medicines help to control symptoms and associated inflammation, but do not, on their own, eliminate Barrett’s tissue. Nor do they replace endoscopic monitoring where indicated. Treatment should be tailored to the extent of Barrett’s, the biopsy results, the person’s age, general health and personal preferences.

Follow-up without dysplasia

Most people diagnosed do not have dysplasia. In these cases, preventive surgical removal of the tissue is not usually indicated. Regular endoscopic monitoring is recommended to detect any potential changes before they progress. The intervals between check-ups depend mainly on the length of the Barrett’s segment and the quality of the previous examination.

European guidelines generally recommend less frequent follow-ups when the Barrett’s segment is short and more frequent follow-ups when it is extensive. Lesions smaller than one centimetre are not usually included in surveillance programmes. Age, other medical conditions, the expected benefit and personal preferences must also be taken into account when deciding whether to continue with follow-up. Surveillance is therefore tailored to each individual’s risk and clinical situation.

Treatment of dysplasia

When high-grade dysplasia is confirmed, endoscopic treatment is usually recommended to remove the abnormal tissue and reduce the risk of progression. Endoscopic treatment may also be proposed for low-grade dysplasia. In certain cases, it is reasonable to continue with close monitoring after explaining the benefits, potential adverse effects and available alternatives.

If there is a visible lesion, it is usually removed first by endoscopic resection. This technique allows the suspicious area to be removed and analysed more precisely to determine the depth of the abnormalities. Ablation of the remaining tissue can then be carried out. Ablation involves the controlled destruction of Barrett’s epithelium to encourage its replacement by a normal-appearing oesophageal lining. The most commonly used technique is radiofrequency ablation, although cryotherapy may also be used in certain centres and situations. The treatment usually requires several sessions and must be carried out in centres with relevant experience.

Surgical treatment

Surgery is no longer the standard treatment for dysplasia or for many very superficial cancers, as endoscopic techniques allow numerous cases to be treated whilst preserving the oesophagus. It may be necessary when the tumour invades deeper layers, lymph nodes are involved, or the lesion cannot be safely removed by endoscopy.

Anti-reflux surgery may be considered to treat certain cases of gastro-oesophageal reflux disease. However, it is not indicated as a specific strategy to reduce the cancer risk associated with Barrett’s oesophagus. Before any decision regarding surgery is made, it is necessary to assess the extent of the disease, the function of the oesophagus and the patient’s general condition.

Barrett’s oesophageal dysplasia

Dysplasia is an abnormal change in the cells of the oesophagus that indicates an increased risk of progression. Its presence and grade are key factors in determining the follow-up or treatment strategy. It can be classified as low-grade or high-grade dysplasia, depending on the severity of the changes observed under a microscope. The higher the grade, the greater the risk and the more likely it is that endoscopic treatment will be recommended.

Occasionally, the results of biopsies are considered inconclusive for dysplasia. This means that inflammation or other changes prevent a definitive determination of whether precancerous changes are present. In such cases, it may be necessary to improve reflux control and repeat the endoscopy. The diagnosis of dysplasia must be confirmed by a pathologist with experience in gastrointestinal diseases, as interpretation can be complex and there are differences between observers.

When there is no dysplasia, the risk of progression is usually low and regular monitoring is typically maintained. When dysplasia is present, follow-up and treatment must be tailored to its grade.

Progression and follow-up

Barrett’s oesophagus increases the risk of oesophageal adenocarcinoma, although the absolute risk remains low in most people who do not have dysplasia. The risk increases when the affected segment is long, dysplasia is present, there is a family history, or other clinical factors are present.

Progression usually occurs through gradual cellular changes. This progression allows many precancerous changes to be detected and treated during endoscopic surveillance. Follow-up is tailored to individual risk and helps determine when regular monitoring is sufficient and when intervention is advisable.

Follow-up after endoscopic treatment

The complete removal of dysplasia and Barrett’s oesophagus significantly reduces the risk of progression, but requires continued follow-up. The abnormal tissue may recur, particularly near the junction between the oesophagus and the stomach. For this reason, periodic endoscopies are carried out after treatment.

It is also necessary to continue managing reflux and to take the prescribed medication correctly. During follow-up, the treated area is examined, biopsies are taken where appropriate, and any small residual or recurrent areas are treated. The frequency of check-ups depends on the grade of dysplasia or the type of lesion that was present before treatment.

Situations requiring special attention

Follow-up is particularly important when biopsies show dysplasia, the Barrett’s oesophagus is extensive or there is a visible lesion. Careful assessment is also required when there is a family history of oesophageal adenocarcinoma, progressive difficulty swallowing, gastrointestinal bleeding, anaemia or unintentional weight loss.

In people who have undergone endoscopic treatment, it is important to continue with follow-up checks even if the abnormal tissue has been completely removed. A diagnosis of short Barrett’s oesophagus, without dysplasia and having been properly assessed, usually allows for less frequent follow-up appointments and a normal daily life.

Specialists involved

The care pathway for Barrett’s oesophagus may vary depending on the reason for consultation, the endoscopic findings and the results of the biopsies. Not everyone needs to see the same specialists: in many cases, diagnosis and follow-up are handled entirely within the Gastroenterology Department.

Where Barrett’s oesophagus is suspected, or where it is necessary to confirm its extent, take biopsies or carry out endoscopic surveillance, the Digestive Endoscopy Unit at the Publio Cordón Memorial Hospital may be involved. This unit forms part of the Digestive System Department and has the capacity to carry out diagnostic and therapeutic procedures, including those for complex digestive disorders.

Biopsies are examined by specialists in Pathology, whose role is particularly important when it is necessary to confirm the presence and grade of dysplasia. In such cases, the histological interpretation directly influences subsequent decisions regarding surveillance or treatment.

If dysplasia or a visible lesion suitable for endoscopic treatment is detected, follow-up care requires specialised expertise in advanced therapeutic endoscopy. The aim may be to remove a specific lesion via endoscopic resection and, where indicated, to subsequently treat the remaining Barrett’s oesophagus. The hospital’s own Gastrointestinal Endoscopy Unit carries out both diagnostic and therapeutic endoscopic procedures.

In a smaller proportion of patients, the findings may necessitate the assessment of surgical options. At this stage, the Department of General and Gastrointestinal Surgery may become involved, particularly when a lesion cannot be adequately treated by endoscopy or there is evidence of deeper-seated disease.

If the investigation confirms oesophageal cancer requiring an oncological approach, the care pathway is expanded. Depending on the characteristics and extent of the disease, Medical Oncology, Radiation Oncology, Surgery and Diagnostic Imaging may be involved to complete staging and plan treatment. Memorial Publio Cordón Hospital has these departments within its healthcare and oncology structure.

The involvement of various specialists does not mean that everyone with Barrett’s oesophagus requires a complex approach. The care pathway is progressively adapted based on the findings from endoscopy, biopsies and, where necessary, other tests. A person without dysplasia may primarily require follow-up by the Gastroenterology Department, whilst the appearance of a lesion or significant cellular changes may require therapeutic endoscopy, surgery or consultation with other specialists.

Living with Barrett’s oesophagus

Receiving the diagnosis can cause concern due to its link with cancer. In most people without dysplasia, the risk of progression is low and follow-up is tailored to the characteristics of each individual case. Appropriate monitoring allows cellular changes to be detected before they cause symptoms and treated using minimally invasive techniques where necessary.

In day-to-day life, recommendations usually focus on managing reflux, maintaining a healthy weight, not smoking and taking prescribed medication as directed. There is no need to adopt extreme diets or live in constant fear of every minor discomfort. Reflux symptoms and the risk of progression do not always go hand in hand.

A person may feel well and still require monitoring, just as they may experience heartburn without Barrett’s having worsened. Monitoring should be based on endoscopies and biopsies, not solely on the presence or absence of symptoms. With individualised monitoring and treatment when indicated, Barrett’s oesophagus can be managed for many years through structured clinical follow-up.

Medical information for general guidance

The purpose of this content is to facilitate understanding of Barrett’s oesophagus, its relationship with gastro-oesophageal reflux, the significance of dysplasia, the diagnostic process, and the options for monitoring or treatment. It also aims to help explain why follow-up may differ from person to person and in which situations a specialist assessment is advisable.

At the Publio Cordón Memorial Hospital, we believe it is important for medical information to be accurate, understandable and useful in guiding each individual throughout their care journey. Our specialists devote part of their work to explaining conditions, tests and treatment options in an accessible way, helping patients and their families to better understand each stage and participate with greater confidence in decisions about their health. This commitment to knowledge and public outreach is also part of our dedication to research and the advancement of medicine.

The information provided in this leaflet is general in nature and cannot be used to establish a diagnosis or recommend individual treatment. A medical assessment must take into account symptoms, medical history, test results and the specific circumstances of each individual.

In the event of severe symptoms, those that appear suddenly, or those consistent with a potential medical emergency, a proper medical assessment is required.